Published in J Virol on July 01, 2006
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem (2008) 0.98
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 7.08
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science (1991) 5.42
Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov (2005) 4.46
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A (2000) 3.26
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci U S A (1998) 2.98
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A (1999) 2.69
A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem (1996) 2.58
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol (2002) 2.54
Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol (1998) 2.49
Adherence to HAART regimens. AIDS Patient Care STDS (2003) 2.27
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
Type II restriction endonucleases: structural, functional and evolutionary relationships. Curr Opin Chem Biol (1999) 1.79
Structure and function of HIV-1 integrase. Curr Top Med Chem (2004) 1.74
Twenty years of therapy for HIV-1 infection. Nat Med (2003) 1.62
Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem (2003) 1.55
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res (1994) 1.47
Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J Biol Chem (1997) 1.47
S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs (2003) 1.31
4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem (2000) 1.30
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem (2002) 1.26
Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol (1998) 1.25
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol (2000) 1.17
In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol (2001) 1.15
New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol (2002) 1.13
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 1.10
HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem (2004) 1.10
Adherence practices among people living with HIV. AIDS Care (2003) 1.09
Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J Med Virol (2001) 1.09
Structural determinants of metal-induced conformational changes in HIV-1 integrase. J Biol Chem (1998) 1.08
HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev (2005) 1.04
Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants. Biophys J (2005) 1.04
Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol (2004) 1.02
Emerging anti-HIV drugs. Expert Opin Emerg Drugs (2005) 0.92
In search of authentic inhibitors of HIV-1 integration. Antivir Chem Chemother (2002) 0.92
HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr Top Med Chem (2004) 0.91
A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett (2005) 0.91
Biochemical and random mutagenesis analysis of the region carrying the catalytic E152 amino acid of HIV-1 integrase. Nucleic Acids Res (2004) 0.90
Reversal of HIV-phenotype to fulminant replication on macrophages in perinatal transmission. Lancet (1989) 0.90
A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity. Antivir Chem Chemother (2005) 0.85
Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res (2004) 0.81
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Nucleotide sequence and expression of the selenocysteine-containing polypeptide of formate dehydrogenase (formate-hydrogen-lyase-linked) from Escherichia coli. Proc Natl Acad Sci U S A (1986) 4.07
Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology (1992) 2.88
Cotranslational insertion of selenocysteine into formate dehydrogenase from Escherichia coli directed by a UGA codon. Proc Natl Acad Sci U S A (1987) 2.72
Organization of immature human immunodeficiency virus type 1. J Virol (2001) 2.34
American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc (2000) 2.32
Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A (1994) 2.31
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene (1997) 2.25
Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care (1997) 2.19
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1995) 2.04
The product of the SNF2/SWI2 paralogue INO80 of Saccharomyces cerevisiae required for efficient expression of various yeast structural genes is part of a high-molecular-weight protein complex. Mol Microbiol (1999) 1.99
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning. J Med Virol (1987) 1.92
Factors affecting transcriptional regulation of the formate-hydrogen-lyase pathway of Escherichia coli. Arch Microbiol (1987) 1.89
Behavioral science in diabetes. Contributions and opportunities. Diabetes Care (1999) 1.85
Cooperative assembly of simian virus 40 T-antigen hexamers on functional halves of the replication origin. J Virol (1991) 1.78
The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS (1995) 1.69
Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother (1999) 1.67
Intracellular transport of retroviral capsid components. Curr Top Microbiol Immunol (1996) 1.67
The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8.1. J Virol (1998) 1.66
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A (1996) 1.58
PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc Natl Acad Sci U S A (1998) 1.57
Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res (1999) 1.48
The use of isothermal heat conduction microcalorimetry to evaluate drug stability in tablets. Int J Pharm (1999) 1.45
A highly divergent HIV-2-related isolate. Nature (1990) 1.45
HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype. J Acquir Immune Defic Syndr (1992) 1.42
Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology (1994) 1.37
Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm (2000) 1.37
Identification of polymers as major components of atmospheric organic aerosols. Science (2004) 1.36
Neither type of mannose 6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes. J Cell Biol (1996) 1.36
Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother (1993) 1.35
Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm (2000) 1.33
Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther (2006) 1.32
Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res (2002) 1.27
Isolation of variants of lymphocytopathic retroviruses from the peripheral blood and cerebrospinal fluid of patients with ARC or AIDS. J Med Virol (1986) 1.26
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl. Proc Natl Acad Sci U S A (1987) 1.24
Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors. Virology (2001) 1.23
Structure, expression and chromosomal mapping of TKT from man and mouse: a new subclass of receptor tyrosine kinases with a factor VIII-like domain. Oncogene (1993) 1.22
Analysis of hepatitis C virus core protein interaction domains. J Gen Virol (1997) 1.21
Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol (2001) 1.20
Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase. Proc Natl Acad Sci U S A (1991) 1.20
Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol (1997) 1.19
In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology (1997) 1.14
Downstream activation of a TATA-less promoter by Oct-2, Bob1, and NF-kappaB directs expression of the homing receptor BLR1 to mature B cells. J Biol Chem (1998) 1.11
Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake. J Microencapsul (2000) 1.10
Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release (2006) 1.10
Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res (1997) 1.10
Systematic classification of HIV biological subtypes on lymphocytes and monocytes/macrophages. Virology (1990) 1.09
Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul (1998) 1.07
Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. AIDS (1997) 1.07
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem (1998) 1.06
Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity. J Biol Chem (1996) 1.05
Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res (2000) 1.05
Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target (2001) 1.03
A developmentally regulated aconitase related to iron-regulatory protein-1 is localized in the cytoplasm and in the mitochondrion of Trypanosoma brucei. J Biol Chem (2000) 1.03
Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm (2007) 1.03
PCR mediated detection of a new human receptor-tyrosine-kinase, HEK 2. Oncogene (1993) 1.02
Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. J Virol (2000) 1.01
Mutations in trans which affect the anaerobic expression of a formate dehydrogenase (fdhF) structural gene. Arch Microbiol (1989) 1.01
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J Virol (1994) 1.00
Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood (1996) 1.00
Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm (2000) 1.00
Prevalence of the metabolic syndrome in the island of Gran Canaria: comparison of three major diagnostic proposals. Diabet Med (2005) 0.99
Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions. Oncogene (1998) 0.98
Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother (1996) 0.98
Hypoglycemia and driving performance: a flashing yellow light? Diabetes Care (2000) 0.96
Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years of experience from 591 procedures in 419 patients. Acta Radiol (1998) 0.96
Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Target (1999) 0.96
Immunoglobulin class- and subclass-specific HIV antibody detection in serum and CSF specimens by ELISA and Western blot. Infection (1987) 0.95
Oligosaccharide profiles of HIV-2 external envelope glycoprotein: dependence on host cells and virus isolates. Glycobiology (1994) 0.95
Isolation and characterization of a human gene that encodes a new subclass of protein tyrosine kinases. Gene (1992) 0.95
Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrob Agents Chemother (1994) 0.94
Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci (2000) 0.94
Long-term clinical results of percutaneous transluminal angioplasty in transplant renal artery stenosis. Nephrol Dial Transplant (1992) 0.94
Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera. Med Microbiol Immunol (1990) 0.93
Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine. Drug Metab Dispos (1990) 0.93
Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res (1992) 0.93
Spread of HIV-2 in India. Lancet (1991) 0.93
T cells for suicide gene therapy: activation, functionality and clinical relevance. J Immunol Methods (2007) 0.93
Chronic lateral epicondylitis of the elbow: A prospective study of low-energy shockwave therapy and low-energy shockwave therapy plus manual therapy of the cervical spine. Arch Phys Med Rehabil (2001) 0.93
Effects of binge pattern cocaine administration on dopamine D1 and D2 receptors in the rat brain: an in vivo study using positron emission tomography. J Neurosci (1996) 0.92
Systematic studies on parameters influencing the performance of the polymerase chain reaction. J Clin Chem Clin Biochem (1990) 0.92
Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr (1991) 0.92
Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm Res (1992) 0.92
Nanoparticles and nanocapsules--new dosage forms in the nanometer size range. Pharm Acta Helv (1978) 0.92
Vaccine adjuvant effects, and immune response, to synthetic polymers MVE and poly ICLC. Prog Clin Biol Res (1984) 0.91
Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene (1996) 0.91
Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett (2002) 0.91
Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J Microencapsul (1993) 0.90
Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli - two tags tie it up. Eur J Biochem (1999) 0.90